Comparative assessment of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus and Saccharomyces boulardii efficacy at diarrheal variant of irritable bowel syndrome

Aim of investigation. To estimate effect of probiotics on severity of clinical symptoms, presence of bacterial overgrowth syndrome (BOS) and quality of life at diarrheal variant of irritable bowel syndrome (IBS-D).

Material and methods. In 47 patients with diagnosis of IBS-D, confirmed by conformity of symptoms to Rome-III criteria and absence of organic diseases according to carried out investigation comparative analysis of effect of probiotics and placebo on development of main clinical symptoms, state of intestinal microflora and quality of life was applied. Efficacy of probiotics containing microorganisms Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus (Florasan-D); yeast Saccharomyces boulardii (Enterol) was studied. Overall 25 men (53,2 %) and 22 women (46,8 %) with mean age 33 year (31,5; 37,8) were investigated. Probiotics Florasan-D, Enterol and placebo were prescribed in a doze of 250 mg bid. Intensity of abdominal pain and meteorism was estimated by visual analog scale (VAS), consistency of stool – by Bristol stool form scale, defecation rate — by calculation of number of bowel movements during every week of treatment. Besides that presence of BOS was investigated by hydrogen breath test with lactulose, quality of a life was determined using The Short Form-36 (SF-36) questionnaire prior to treatment onset and its termination. Treatment lasted for 28 days.

Results. In group of the patients who received Florasan-D and Enterol, in contrast to as placebo group improvement in relation to severity of main clinical symptoms was marked, quality of a life score increased. Besides that, according to hydrogen breath test with lactulose results on a background of Florasan-D it was possible to eliminate BOS in all patients.

1. Ардатская М. Ф. Клиническое значение короткоцепочечных жирных кислот при патологии желудочнокишечного тракта: Дис. … д-ра мед. наук. М., 2003.

2. Воробьев А. А. Микробиология и иммунология. М.: Медицина, 1999.

3. Звягинцева Т. Д., Гриднева С. В. Синдром раздраженного кишечника, дисбиоз, Энтерожермина. Новости медицины и фармации 2009; 17(291).

4. Ивашкин В. Т., Полуэктова Е. А. Функциональные расстройства желудочно-кишечного тракта. М.: МЕДпресс-информ, 2013.

5. Ивашкин В. Т., Денисов Н. Л. Местный иммунитет и микробиоценоз при заболеваниях кишечника. Рос журн гастроэнтерол гепатол колопроктол 2009; 19(6):11-6.

6. Курбатова А. А. Патогенетическое и клиническое значение системы цитокинов и клаудинов у больных с синдромом раздражённого кишечника: Дис. … канд. мед. наук. М., 2013.

7. Кучумова С. Ю., Полуэктова Е. А., Шептулин А. А., Ивашкин В. Т. Физиологическое значение кишечной микрофлоры. Рос журн гастроэнтерол гепатол колопроктол 2011; 21(5):17-27.

8. Копанев Ю. А. Взаимосвязь функции местного иммунитета и микробиоценоза кишечника, возможности иммунокоррекции дисбактериоза. Лечащий врач 2009; 9:66-9.

9. Полуэктова Е. А., Кучумова С. Ю., Шифрин О. С., Шептулин А. А., Ивашкин В. Т. Патогенетическое значение изменений кишечной микрофлоры у больных с синдромом раздраженного кишечника и возможности их коррекции. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(3):89-97.

10. Рассохина О. А. Влияние серотонина на психологический статус у больных с синдромом раздраженной кишки. Гастроэнтерология 2010; 313:25-7.

11. Спиваковский Ю. М., Шульгина Е. Н., Эйберман А. С., Герасименко Ю. К., Скупова О. В. Синдром раздраженного кишечника у детей в свете «Римских критериев III» и роль иммуномодулирующей терапии в коррекции основных проявлений болезни. Рус мед журн 2010; 18(4):20.

12. Belmonte L., Beutheu Youmba S., Bertiaux-Vandaële N., et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7:427-77.

13. Bertiaux-Vandaële N., Youmba S. B., Belmonte L., et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011; 106:2165-73.

14. Clarke G., Cryan J. F., Dinan T. G., Quigley E. M. Reviewarticle: probiotics for the treatment of irritablebowelsyndrome-focus on lacticacidbacteria. Aliment Pharmacol Ther 2012; 35:403-13.

15. Clarke G., McKernan D.P., et al. A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012; 3:90.

16. Dlugosz A., Lindberg G. The expression of toll-like receptor 4 in colon mucosa is as up-regulated in irritable bowel syndrome as it is in inflammatory bowel disease. Gut 2010; 59:A31.

17. Ford A. C., Quigley E. M., Lacy B. E., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014; 109:2-26.

18. Furuse M., Hirase T., Itoh M., et al. Occludin: a novel integral membrane protein at tight junctions. J Cell Biol 1993; 123:1777-88.

19. Ghoshal U. C., Kumar S., Mehrotra M., Lakshmi C., Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil 2010; 16:40-6.

20. Greer J. B., O’Keefe S. J. Microbial induction of immunity, inflammation and cancer. Front Physiol 2011; 1:168.

21. Hosseini A., Nikfar S., Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012; 12:1323-34.

22. Hoveyda N., et al. A systematic review and metaanalysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9:15.

23. Kellow J. E., Eckersley G. M., Jones M. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome. Dig Dis Sci 1992; 37:168-74.

24. Kerckhoffs A. P., Samsom M., van der Rest M. E., et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15:2887-92.

25. Khan M. W., Kale A. A., Bere P., Vajjala S., Gounaris E., Pakanati K. C. Microbes, intestinalinflammation and probiotics. Expert Rev Gastroenterol Hepatol 2012; 6:81-94.

26. Lewis S. J., Heaton K. W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32(9):920-24.

27. Majewski M., McCallum R. W. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52:139-42.

28. Malinen E., Rinttilä T., Kajander K., et al. Analysis of the microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-82.

29. Ng S. C., Hart A. L., Kamm M. A., Stagg A. J., Knight S. C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15:300-10.

30. Nucera G., Gabrielli M., Lupascu A., et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 21:1391-5.

31. Ohland С., MacNaughton К. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol, Gastrointest Liver Physiol 2010; 298:807-19.

32. Ohman L., Lindmark A. C., Isaksson S., et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24(4):398-405.

33. Parkes G. C., Rayment N. B., Hudspith B. N., et al. Distinct microbial populations exist in the mucosaassociated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:31-9.

34. Pimentel M., Chow E. J., Lin H. C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. А double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98:412-9.

35. Quigley E. M. Intestinal dysmotility and the irritable bowel syndrome. Ir J Med Sci 1994; 163:560-1.

36. Quigley E. M. Microfloramodulation of motility. J Neurogastroenterol Motil 2011; 17:140-7.

37. Rajilić-Stojanović М., et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141:1792-801.

38. Shah E. D., Basseri R. J., Chong K., Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010; 55:2441-9.

39. Turksen K., Troy T. C. Barriers built on claudins. J Cell Sci 2004; 117:2435-47.

40. Ware J. E., Snow K. K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass, 1993.

41. Weaver M. E., Lowe N. K. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990; 13(4):227-36.

42. Zhou Q., Souba W. W., Croce C. M., Verne G. N. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59:775-84.